I wonder if this will start to become more common: According to this article in the New York Times today, Eric J. Topol, the chief academic officer of the Cleveland Clinic Foundation, who has had consulting and financial ties with numerous drug and medical device companies including Eli Lilly and Bristol-Myers Squibb, "said in a letter to one company that he had decided to end most of his relationships to 'maintain my academic credibility.'" But did he jump on his own, or was he shoved?
Either way, it's pretty interesting. But if all prominent physicians end up cutting their ties with pharma for whatever reason, that could be disastrous for drug and device research. No easy answers for this one.